Maryland 2022 Regular Session

Maryland House Bill HB1111 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1
2	2
3	3	EXPLANATION: CAPITALS INDICATE MAT TER ADDED TO EXISTIN G LAW.
4	4	[Brackets] indicate matter deleted from existing law.
5	5	hb1111
6	6
7	7	HOUSE BILL 1111
8	8	J1 2lr2500
9	9	HB 1125/21 – HGO
10	10	By: Delegates Beitzel and McComas
11	11	Introduced and read first time: February 11, 2022
12	12	Assigned to: Health and Government Operations
13	13
14	14	A BILL ENTITLED
15	15
16	16	AN ACT concerning 1
17	17
18	18	Prescription Drug Monitoring Program – Prescribers of Opioids – Notification 2
19	19	Requirement 3
20	20
21	21	FOR the purpose of requiring a prescriber to notify the Prescription Drug Monitoring 4
22	22	Program of certain information relating to opioids and opioid reversal drugs if the 5
23	23	prescriber prescribes or dispenses an opioid in a certain dosage; prohibiting a 6
24	24	prescriber from being required to make a certain notification more than once for each 7
25	25	patient; and generally relating to the Prescription Drug Monitoring Program and 8
26	26	prescribers of opioids. 9
27	27
28	28	BY repealing and reenacting, without amendments, 10
29	29	Article – Health – General 11
30	30	Section 21–2A–02(a) 12
31	31	Annotated Code of Maryland 13
32	32	(2019 Replacement Volume and 2021 Supplement) 14
33	33
34	34	BY repealing and reenacting, with amendments, 15
35	35	Article – Health – General 16
36	36	Section 21–2A–04.2 17
37	37	Annotated Code of Maryland 18
38	38	(2019 Replacement Volume and 2021 Supplement) 19
39	39
40	40	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 20
41	41	That the Laws of Maryland read as follows: 21
42	42
43	43	Article – Health – General 22
44	44
45	45	21–2A–02. 23
46	46
47	47	(a) There is a Prescription Drug Monitoring Program in the Department. 24
48	48	2 HOUSE BILL 1111
49	49
50	50
51	51	21–2A–04.2. 1
52	52
53	53	(a) (1) Beginning July 1, 2018, a prescriber: 2
54	54
55	55	(i) Shall request at least the prior 4 months of prescription 3
56	56	monitoring data for a patient before initiating a course of treatment for the patient that 4
57	57	includes prescribing or dispensing an opioid or a benzodiazepine; 5
58	58
59	59	(ii) Shall, if a patient’s course of treatment continues to include 6
60	60	prescribing or dispensing an opioid or a benzodiazepine for more than 90 days after the 7
61	61	initial request for prescription monitoring data, request prescription monitoring data for 8
62	62	the patient at least every 90 days until the course of treatment has ended; and 9
63	63
64	64	(iii) Shall assess prescription monitoring data requested from the 10
65	65	Program before deciding whether to prescribe or dispense or continue prescribing or 11
66	66	dispensing an opioid or a benzodiazepine. 12
67	67
68	68	(2) If a prescriber decides to prescribe or continue to prescribe an opioid or 13
69	69	a benzodiazepine after requesting prescription monitoring data from the Program and 14
70	70	assessing the prescription monitoring data, the prescriber shall document in the patient’s 15
71	71	medical record that the prescription monitoring data was requested and assessed. 16
72	72
73	73	(3) (I) SUBJECT TO SUBPARAGRA PH (II) OF THIS PARAGRAPH , IF A 17
74	74	PRESCRIBER PRESCRIBE S OR DISPENSES AN OP IOID IN A DOSAGE OF 50 MORPHINE 18
75	75	MILLIGRAM EQUIVALENT S OR MORE , THE PRESCRIBER SHALL NOTIFY THE 19
76	76	PROGRAM WHETHER THE PATIENT: 20
77	77
78	78	1. HAS RECEIVED EDUCATION R EGARDING THE RISKS 21
79	79	ASSOCIATED WITH OPIO ID USE; 22
80	80
81	81	2. IS AWARE THAT AN OPIO ID OVERDOSE REVERSAL 23
82	82	DRUG IS AVAILABLE ; AND 24
83	83
84	84	3. WAS PRESCRIBED OR DISPEN SED AN OPIOID 25
85	85	OVERDOSE REVERSAL DR UG. 26
86	86
87	87	(II) A PRESCRIBER MAY NOT B E REQUIRED TO M AKE THE 27
88	88	NOTIFICATION REQUIRE D UNDER SUBPARAGRAPH (I) OF THIS PARAGRAPH MO RE 28
89	89	THAN ONCE FOR EACH PATIENT . 29
90	90
91	91	(b) A prescriber is not required to request prescription monitoring data from the 30
92	92	Program if the opioid or benzodiazepine is prescribed or dispensed to an individual: 31
93	93
94	94	(1) In an amount indicated for a period not to exceed 3 days; 32
95	95	HOUSE BILL 1111 3
96	96
97	97
98	98	(2) For the treatment of cancer or cancer–related pain; 1
99	99
100	100	(3) Who is: 2
101	101
102	102	(i) A patient receiving treatment in an inpatient unit of a hospital; 3
103	103
104	104	(ii) 1. A patient in a general hospice care program as defined in 4
105	105	§ 19–901 of this article; or 5
106	106
107	107	2. Any other patient diagnosed with a terminal illness; 6
108	108
109	109	(iii) A patient who resides in: 7
110	110
111	111	1. An assisted living facility; 8
112	112
113	113	2. A long–term care facility; 9
114	114
115	115	3. A comprehensive care facility; or 10
116	116
117	117	4. A developmental disabilities facility; or 11
118	118
119	119	(4) To treat or prevent acute pain for a period of not more than 14 days 12
120	120	following: 13
121	121
122	122	(i) A surgical procedure; 14
123	123
124	124	(ii) A fracture; 15
125	125
126	126	(iii) Significant trauma; or 16
127	127
128	128	(iv) Childbirth. 17
129	129
130	130	(c) A prescriber may not be required to comply with the provisions of this section 18
131	131	when: 19
132	132
133	133	(1) Prescribing or dispensing an opioid or a benzodiazepine drug that has 20
134	134	been listed by the Secretary under § 21–2A–03(b)(3) of this subtitle as having a low 21
135	135	potential for abuse; 22
136	136
137	137	(2) Accessing prescription monitoring data would result in a delay in the 23
138	138	treatment of a patient that would negatively impact the medical condition of the patient; 24
139	139
140	140	(3) Electronic access to prescription monitoring data is not operational as 25
141	141	determined by the Department; or 26
142	142
143	143	(4) Prescription monitoring data cannot be accessed by the prescriber due 27
144	144	to a temporary technological or electrical failure. 28 4 HOUSE BILL 1111
145	145
146	146
147	147
148	148	(d) If a prescriber does not access prescription monitoring data for any of the 1
149	149	reasons provided under subsection (c)(2), (3), or (4) of this section: 2
150	150
151	151	(1) The prescriber shall use reasonable medical judgment in determining 3
152	152	whether to prescribe or dispense an opioid or a benzodiazepine; and 4
153	153
154	154	(2) The prescriber shall enter an appropriate record in the patient’s 5
155	155	medical chart, including the reason why prescription monitoring data was not accessed. 6
156	156
157	157	(e) If a pharmacist or pharmacist delegate has a reasonable belief that a patient 7
158	158	may be seeking a monitored prescription drug for any purpose other than the treatment of 8
159	159	an existing medical condition: 9
160	160
161	161	(1) Before dispensing a monitored prescription drug to the patient, the 10
162	162	pharmacist or pharmacist delegate shall request prescription monitoring data to determine 11
163	163	if the patient has received other prescriptions that indicate misuse, abuse, or diversion of 12
164	164	a monitored prescription drug; and 13
165	165
166	166	(2) The pharmacist shall have the responsibility described in 21 C.F.R. § 14
167	167	1306.04. 15
168	168
169	169	(f) The Secretary may adopt regulations to provide additional clinical, technical, 16
170	170	or administrative exemptions based on new standards of practice. 17
171	171
172	172	SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect 18
173	173	October 1, 2022. 19
174	174